Company intelligence / Profile preview
Inosan Biopharma
- Ownership
- Private
- Employees
- ~22
- Development stage
- Commercial
01
Overview
Inosan Biopharma has commercially available antivenoms for Sub-Middle East and North African snake bites, Sub-Saharan African snake bites, and Middle East and North African scorpion stings. They have multiple products in various clinical stages, including a Coral Snake Antivenom in Phase III and a North America Anti-Snake Antivenom in registration phase. They also conducted a Phase I clinical trial for anti-SARS-CoV-2 equine antibody F(ab')2 fragments (INOSARS) in patients with mild COVID-19[1][8][10].
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Antibody-based therapeuticsF(ab')2 Immunoglobulin Fragments (Equine)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on Inosan Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inosan Biopharma.